How do the primary analysis results of the MIRASOL trial differ from the primary analysis results? Were there any unexpected findings? Back then, when we did the primary analysis, we had a follow ...

In the Phase III MIRASOL trial, Elahere (mirvetuximab soravtansine-gynx) significantly improved progression-free survival and overall survival compared to chemotherapy in patients with folate receptor ...

The randomized, phase 3 MIRASOL trial included 453 patients with FRα+, platinum-resistant ovarian cancer who received either mirvetuximab soravtansine (n = 227) or investigator’s choice ...

Sales and distribution of medicinal cannabis products in Australia and the United Kingdom, and the construction of a cannabis extraction and manufacturing facility in Canada.

Elahere shows a 37% lower risk of tumor progression or death vs. chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. A Cedar Rapids man, who state troopers pulled over in October 2023 and found he had a dead man in ...

Roblox is an online game platform where users can create their own games and also join games created by other users. There are lots of different Roblox codes floating around, to be honest! Some of the ...

The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. IOWA CITY — It’s been a while since Iowa has searched for a new men’s basketball coach ...

Nitura put up 35 kills and three aces while Althea Aposaga backed her up with 18 points. Those efforts, however, were not enough as the Maroons produced four players with 15 or more points. Nina Ytang ...

New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, demonstrated a confirmed objective response rate of 55.6%. Genmab has shared ...